

ONCOLOGY PROGRAM		
8 OCTOBER 2019		
10.00 - 12.00	Cancer Immunotherapy in Lung Cancer Course	Başak Oyan Uluç - Berksoy Sahin
13.20 - 13.30 OPENING REMARKS - Berksoy Sahin, Jean - Francois Rossi		
13.30 - 15.00	SESSION I - PRECISION AND MOLECULAR ONCOLOGY	CHAIRS: Uğur Yılmaz
13.30 - 13.55	Touching Cell Cycle and DNA Repairing: CDK Inhibitors and PARP Inhibitors in Solid Tumors	Uğur Yılmaz
13.55 - 14.20	The Bio-Informatics of Precision Cancer Medicine	Tariq Mughal
14.20 - 14.45	How Do Molecular Panels Help Me Make Clinical Decisions About My Patients?	Prasad Adusumilli
14.45 - 15.00	Q & A	
15.00 - 15.30 COFFEE BREAK		
15.30 - 18.00	SESSION II - IMMUNE ONCOLOGY (BASIC)	CHAIRS: Jean-Francois Rossi, Martin Villalba , Nikolay Tupitsyn, Berksoy Sahin
15.30 - 15.55	Precision Immune Medicine in cancer	Jean-Francois Rossi
15.55 - 16.20	Glycan-specific natural antibodies : from diagnosis to therapy in cancer	Nikolay Tupitsyn
16.20 - 16.45	Natural Killer Cells in Oncology	Martin Villalba
16.45 - 17.10	Cancer Vaccine : A New Therapeutic Way	Patrick Fraysin
17.10 - 17.35	Concluding Remarks in Immune Therapy	Jean-Francois Rossi, Martin Villalba , Nikolay Tupitsyn
17.35 - 18.00	Q & A	
9 OCTOBER 2019		
08.30 - 10.00	SESSION III - IMMUNE ONCOLOGY (CLINIC)	CHAIRS: Jean-Francois Rossi, Berksoy Sahin
08.30 - 08.55	Allogenic Transplantation as a Model for Immune Therapy in Oncology	Patrice Ceballos
08.55 - 09.20	mAb Biosimilars	Bulent Gümüsel
09.20 - 09.45	CAR T Therapy for Solid Tumors	Prasad Adusumilli
09.45 - 10.00	Q & A	
10.00 - 10.30 COFFEE BREAK		
10.30 - 12.00	SESSION IV - HEAD AND NECK CANCER	CHAIRS: Musa Altun, Rasim Meral
10.30 - 10.55	HPV-Associated Head/Neck Cancer: New Stagings and New Treatments	Kübra Özkaya Toraman
10.55 - 11.20	Tumor-Related Factors Warranting Adjuvant Postoperative Therapy in Head and Neck Cancer	Musa Altun
11.20 - 11.45	p16-Negative Advanced Head and Neck Cancer	Bora Basaran
11.45 - 12.00	Q & A	
12.00 - 13.00 LUNCH BREAK		
13.00 - 14.30	SESSION V - NON-SMALL CELL LUNG CANCER	CHAIRS: Perran Fulden Yumuk
13.00 - 13.25	Sequencing Agents in the Management of EGFR Mutation Positive Non-Small Cell Lung Cancer	Mustafa Erman
13.25 - 13.50	Management of ALK Non-Small Cell Lung Cancer Through First and Subsequent Lines of Therapy	Fulden Yumuk
13.50 - 14.15	Immunotherapy in Small and Non-small Cell Lung Cancer; The Role of Immune Checkpoint Inhibitors in Frontline and Beyond Frontline Therapy	Başak Oyan Uluç
14.15 - 14.30	Q & A	
14.30 - 15.00 COFFEE BREAK		
15.00 - 16.30	SESSION VI - EARLY BREAST CANCER	CHAIRS: Ozlem Er, Hasan Şenol Coşkun
15.00 - 15.25	Challenging Adjuvant Therapy in HER2+ Breast Cancer: Escalating or De-escalating ?	Çağatay Arslan
15.25 - 15.50	Evolving Approaches in Systemic Therapy for Triple-Negative Breast Cancer in Neoadjuvant and Adjuvant Settings	Ozlem Er
15.50 - 16.15	Adjuvant Therapy in ER+ HER2- Breast Cancer: Chemotherapy or Not?	Mehmet Ali Kaplan
16.15 - 16.30	Q & A	
16.30 - 18.00	SESSION VII - COLORECTAL CANCER	CHAIRS: Mahmut Gümüş
16.30 - 16.55	Is Shortening the Duration of Adjuvant Treatment is Eligible in Early Staged Colon Cancer?	Ece Esin
16.55 - 17.20	Is Tumor Sidedness, Biomarkers or Molecular Subtype Classification More Predictive for the Treatment of Unresectable Metastatic Colon Cancer?	Gökhan Demir
17.20 - 17.45	Systemic Therapy for Potentially Resectable Metastatic Rectal Cancer	Dilek Erdem
17.45 - 18.00	Q & A	
10 OCTOBER 2019		
08.30 - 11.00	SESSION VIII - NON - COLORECTAL TUMORS	CHAIRS: Şuayib Yalçın, Özlem Er
08.30 - 08.55	New (neo-)adjuvant Standards of Care in Gastro-esophageal Cancer	Mehmet Artaç
08.55 - 09.20	What is Changed in the Treatment of Biliary Tract Cancer?	Fatih Köse
09.20 - 09.45	Has Sorafenib Still Been the Real Winner Against New Generation TKIs and Immune Checkpoint Inhibitors in HCC?	Şahin Laçın
09.45 - 10.10	Treatment for recurrent disease following Adjuvant treatment of GIST	Maxim Nikulin
10.10 - 10.35	Metastatic Well-Differentiated Gastrointestinal Neuroendocrine (Carcinoid) Tumors: Systematic Therapy Options	Alexander Kuzminov
10.35 - 11.00	Q & A	
11.00 - 11.30 COFFEE BREAK		
11.30 - 13.00	SESSION IX - ADVANCED / METASTATIC BREAST CANCER	CHAIRS: Berna Öksüzöğlü, Bülent Orhan
11.30 - 11.55	Optimizing Therapy for ER-Positive Metastatic Breast Cancer	Sema Sezgin Gökse
11.55 - 12.20	Overcoming Resistance in HER2+ Metastatic Breast Cancer	Sernaz Uzunoğlu
12.20 - 12.45	Shining Side of the Moon; PARP Inhibitors in Triple Negative Breast Cancer	Ömer Dızdar
12.45 - 13.00	Q & A	
13.00 - 14.00 LUNCH BREAK		

14.00 - 16.00	SESSION X - URO-ONCOLOGY	CHAIRS: Mustafa Erman
14.00 - 14.25	Approach to Stage I Testicular Cancer: Who Needs Treatment and Which One?	Ömer Dizdar
14.25 - 14.50	Treatment of Cisplatin-Ineligible Metastatic Bladder Cancer	Aziz Karaoğlu
14.50 - 15.15	What is the Role and Best Sequencing of the New Generation Hormonal Agents in the Treatment of Both Hormone Sensitive and Resistant Metastatic Prostate Cancer?	Mustafa Erman
15.15 - 15.40	Perioperative Systemic Therapy for Localized Renal Cell Carcinoma: To Treat or Not to Treat ?	Çağatay Arslan
15.40 - 16.00	Q & A	
16.00 - 17.30	SESSION XI - SKIN CANCER	CHAIRS: İsmail Çelik - Tarkan Yetişyigit
16.00 - 16.25	Update on neoadjuvant/adjuvant treatment of melanoma:	Hande Turna
16.25 - 16.50	Markers for immune checkpoint inhibitor resistance	Selçuk Seber
16.50 - 17.15	The evolution of metastatic melanoma treatment. What's next?	Dilek Erdem
17.15 - 17.30	Q & A	
17.30 - 19.00	SESSION XII - SARCOMA	CHAIRS: Berksoy Şahin
17.30 - 17.55	Molecular and morphological diagnosis in bone and soft tissue tumors	Marco Gambarotti
17.55 - 18.20	Small round cell tumors	Kvılcım Eren Erdoğan
18.20 - 18.45	Can We Ever Have a Specific Treatment for Every 50 Subtypes of Soft Tissue Sarcoma?	Çiğdem Usul Afşar
18.45 - 19.00	Q & A	
19.00	CLOSING	